Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
ID: 347718Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347718

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-179.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program seeks to support innovative projects that enhance the prevention, diagnosis, treatment, and care for individuals affected by AD/ADRD, while also addressing the shortage of scientists in this critical research area. Eligible applicants include a wide range of institutions, such as higher education institutions, community-based organizations, and tribal colleges, with funding of up to $100,000 per year available for projects lasting a maximum of two years. Applications are accepted on a rolling basis until March 17, 2026, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-179.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-179-Full-Announcement.html
    PAR-23-179.html
    The National Institutes of Health (NIH) has reissued the Small Research Grant Program (R03) targeting emerging researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The program aims to stimulate innovative research to enhance prevention, diagnosis, treatment, and caregiving for individuals with AD/ADRD while addressing the shortage of scientists in this critical area. The program encourages applications from early stage investigators and researchers lacking major prior funding in the field. Funding of up to $100,000 per year is available for projects lasting a maximum of two years, with an anticipated total of 12 awards worth $1.8 million in fiscal year 2024. Application submissions are due every few months, starting from July 19, 2023, until March 17, 2026. Various research topics are encouraged, ranging from understanding the disease trajectory and identifying health disparities to exploring molecular pathways and behavioral interventions. Eligibility extends to numerous institutional types, including higher education institutions and non-profits. Applications must adhere strictly to specified guidelines, and submissions must be made electronically through the NIH's platform. This initiative reflects NIH's strategic goals to build a diverse workforce equipped to tackle AD/ADRD research challenges.
    Similar Opportunities
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the "Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)." This program aims to support innovative research projects focused on Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), specifically targeting early-stage and diverse researchers who have not previously received significant NIH funding in this field. The initiative is designed to generate pilot data that can lead to larger funding applications, thereby enhancing research capabilities and workforce diversity in biomedical research. Grants of up to $100,000 per year for two years are available, with the application process opening on January 16, 2025, and the closing date set for March 16, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries (LMICs) for Aging and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity through the Small Research Grant Program (R03) aimed at supporting junior faculty researchers in low- and middle-income countries (LMICs) who are focused on aging, Alzheimer's Disease (AD), and AD-related dementias (ADRD). This initiative encourages applications from eligible institutions within LMICs, with the objective of fostering research capacity and career development for junior investigators in these regions. Given the projected increase in older populations and the rising incidence of AD/ADRD in LMICs, this program is critical for addressing global health challenges. Interested applicants can apply for grants of up to $100,000 per year, with a submission deadline of February 14, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing research on Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the Small Business Innovation Research (SBIR) program. This initiative invites U.S. small businesses to submit applications for innovative research projects that could lead to new therapies, diagnostic technologies, or prevention strategies for AD/ADRD. The funding reflects a significant federal commitment to addressing the challenges posed by these conditions, with a total of $20 million anticipated for approximately 40 awards in 2023, providing up to $500,000 for Phase I and $2.5 million for Phase II projects. Interested applicants can find more details and application requirements at the provided link and should note that the application deadline is September 5, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Small Research Grant Program (Parent R03 Clinical Trial Not Allowed), aimed at supporting discrete research projects that can be completed within two years and require limited resources. This program encourages applications for various types of research, including pilot studies, feasibility studies, and the development of new research methodologies, while explicitly excluding clinical trials. With a funding ceiling of $50,000 per year, the program is open to a diverse range of eligible applicants, including higher education institutions, nonprofits, and government entities, particularly those representing historically underrepresented groups. Interested applicants should note that the first submission opportunity opens on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.